Voncento

Voncento combines Human Coagulation Factor VIII and Human Von Willebrand Factor for hemophilia A and von Willebrand disease management. This intravenous therapy supports blood clotting in patients with bleeding disorders. Suitable for adults and children. EU-sourced, prescription required.

Voncento is used to prevent and control bleeding episodes in patients with hemophilia A, a genetic disorder causing insufficient clotting factor VIII. It also treats von Willebrand disease, a condition where blood lacks sufficient von Willebrand factor, impairing clotting. This therapy helps maintain normal blood clotting function during surgeries or injuries.

Voncento works by replenishing missing clotting factors in the bloodstream, temporarily restoring normal clotting ability. After infusion, patients may experience reduced bleeding frequency and severity. The duration of effects varies by individual and treatment plan.

Store Voncento refrigerated between 2°C and 8°C (36°F–46°F) and protect from light. Do not freeze. Use within the labeled expiration date. Discard any unused solution after preparation. Always follow healthcare provider instructions for administration and storage.

Voncento has no known direct drug interactions, but concurrent use with other blood products or clotting agents may increase clotting risk. Inform your doctor about all medications, including over-the-counter and herbal supplements. Avoid alcohol and tobacco, as they may affect clotting function.